Clinical Trials Logo

Advanced Malignant Tumors clinical trials

View clinical trials related to Advanced Malignant Tumors.

Filter by:

NCT ID: NCT06226363 Not yet recruiting - Clinical trials for Advanced Malignant Tumors

Phase I Study of LNF1901 in Advanced Malignant Tumors

Start date: February 1, 2024
Phase: Phase 1
Study type: Interventional

This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.

NCT ID: NCT06223841 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Start date: March 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

NCT ID: NCT06167486 Recruiting - Clinical trials for Advanced Malignant Tumors

SG2918 For Advanced Malignant Tumors

Start date: December 26, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.

NCT ID: NCT05991583 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Start date: June 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with locally advanced or metastatic solid tumors.

NCT ID: NCT05877924 Recruiting - Clinical trials for Advanced Malignant Tumors

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and determine the dose limiting toxicity (DLT), maximum tolerable dose (MTD) (if any), recommended phase II dose (RP2D), and dosing regimen of NBL-020.

NCT ID: NCT05868876 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Start date: June 29, 2023
Phase: Phase 1
Study type: Interventional

A Phase Ia/Ib open label,clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors

NCT ID: NCT05779163 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

NCT ID: NCT05728541 Not yet recruiting - Clinical trials for Advanced Malignant Tumors

Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

The aim of this study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SYH2043 in patients with advanced malignant tumors.

NCT ID: NCT05653284 Not yet recruiting - Clinical trials for Advanced Malignant Tumors

A Study of AK130 in Patients With Advanced Malignant Tumors

Start date: January 2023
Phase: Phase 1
Study type: Interventional

A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.

NCT ID: NCT05396391 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Start date: June 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.